Ligand Pharmaceuticals LGND Accrued Liabilities, Current
Accrued Liabilities, Current at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's accrued liabilities, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's accrued liabilities, current?
- Ligand Pharmaceuticals (LGND) reported accrued liabilities, current of $31.85M in Q1 2026.
- How has Ligand Pharmaceuticals's accrued liabilities, current changed year-over-year?
- Ligand Pharmaceuticals's accrued liabilities, current increased by 35.3% year-over-year, from $23.54M to $31.85M.
- What is the long-term trend for Ligand Pharmaceuticals's accrued liabilities, current?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's accrued liabilities, current has grown at a 11.2% compound annual growth rate (CAGR), from $18.53M to $31.45M.